Miltefosine enhances the fitness of a non-virulent drug-resistantLeishmania infantumstrain
- 8 November 2018
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 74 (2) , 395-406
Abstract
Miltefosine is currently the only oral drug for visceral leishmaniasis, and although deficiency in an aminophospholipid/miltefosine transporter (MT) is sufficient to elicit drug resistance, very few naturally miltefosine-resistant (MIL-R) strains have yet been isolated. This study aimed to make a detailed analysis of the impact of acquired miltefosine resistance and miltefosine treatment on in vivo infection. Bioluminescent versions of a MIL-R strain and its syngeneic parental line were generated by integration of the red-shifted firefly luciferase PpyRE9. The fitness of both lines was compared in vitro (growth rate, metacyclogenesis and macrophage infectivity) and in BALB/c mice through non-invasive bioluminescence imaging under conditions with and without drug pressure. This study demonstrated a severe fitness loss of MT-deficient parasites, resulting in a complete inability to multiply and cause a typical visceral leishmaniasis infection pattern in BALB/c mice. The observed fitness loss could not be rescued by host immune suppression with cyclophosphamide, whereas episomal reconstitution with a wild-type MT restored parasite virulence, hence linking parasite fitness to MT mutation. Remarkably, in vivo miltefosine treatment or in vitro miltefosine pre-exposure significantly rescued MIL-R parasite virulence. The in vitro pre-exposed MIL-R promastigotes showed a longer and more slender morphology, suggesting an altered membrane composition. The profound fitness loss of MT-deficient parasites most likely explains the low frequency of MIL-R clinical isolates. The observation that miltefosine can reverse this phenotype indicates a drug dependency of the MT-deficient parasites and emphasizes the importance of resistance profiling prior to miltefosine administration.Keywords
Funding Information
- Research Fund Flanders
- FWO (G051812N, 12I0317N, 11V4315N)
- L. Van Bockstal (1136417N, 12I0317N)
- University of Antwerp (TT-ZAPBOF 33049)
- Vlaamse Interuniversitaire Raad
- VLIR
- Global Minds Small Research Grants
- European Cooperation in Science and Technology
- COST (CM1307)
- Excellence Centre ‘Infla-Med’
This publication has 44 references indexed in Scilit:
- Highly Sensitive In Vivo Imaging of Trypanosoma brucei Expressing “Red-Shifted” LuciferasePLOS Neglected Tropical Diseases, 2013
- Miltefosine: a review of its pharmacology and therapeutic efficacy in the treatment of leishmaniasisJournal of Antimicrobial Chemotherapy, 2012
- Drug Susceptibility in Leishmania Isolates Following Miltefosine Treatment in Cases of Visceral Leishmaniasis and Post Kala-Azar Dermal LeishmaniasisPLOS Neglected Tropical Diseases, 2012
- Leishmania Resistance to Miltefosine Associated with Genetic MarkerEmerging Infectious Diseases, 2012
- Luciferase-Expressing Leishmania infantum Allows the Monitoring of Amastigote Population Size, In Vivo, Ex Vivo and In VitroPLOS Neglected Tropical Diseases, 2011
- Noninvasive biophotonic imaging for studies of infectious diseaseFEMS Microbiology Reviews, 2011
- Mechanisms of resistance and susceptibility to experimental visceral leishmaniosis: BALB/c mouse versus syrian hamster modelVeterinary Research, 2011
- In Vitro Sensitivity Testing of Leishmania Clinical Field Isolates: Preconditioning of Promastigotes Enhances Infectivity for Macrophage Host CellsAntimicrobial Agents and Chemotherapy, 2009
- In Vitro Susceptibilities of Leishmania donovani Promastigote and Amastigote Stages to Antileishmanial Reference Drugs: Practical Relevance of Stage-Specific DifferencesAntimicrobial Agents and Chemotherapy, 2009
- Genome-wide analysis reveals increased levels of transcripts related with infectivity in peanut lectin non-agglutinated promastigotes of Leishmania infantumGenomics, 2009